Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2022; 28(39): 5679-5690
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5679
Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider
Armando Rojas, Cristian Lindner, Iván Schneider, Ileana Gonzàlez, Miguel Angel Morales
Armando Rojas, Ileana Gonzàlez, Biomedical Research Laboratories, Catholic University of Maule, Talca 34600000, Maule, Chile
Cristian Lindner, Iván Schneider, Medicine Faculty, Catholic University of Maule, Talca 34600000, Maule, Chile
Miguel Angel Morales, Department of Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Santiago 8320000, Santiago, Chile
Author contributions: All authors contributed to the original ideas and writing of this paper; Rojas A designed the report and wrote the paper; Lindner C artwork and data acquisition, drafting and revising the manuscript; Schneider I, Gonzalez I, and Morales MA, data acquisition, drafting and revising the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Armando Rojas, PhD, Full Professor, Senior Scientist, Biomedical Research Labs, Catholic University of Maule, 3605, San Miguel Ave., Talca 34600000, Maule, Chile.
Received: June 27, 2022
Peer-review started: June 27, 2022
First decision: August 1, 2022
Revised: August 5, 2022
Accepted: September 9, 2022
Article in press: September 9, 2022
Published online: October 21, 2022

Compelling evidence derived from clinical and experimental research has demonstrated the crucial contribution of chronic inflammation in the development of neoplasms, including gallbladder cancer. In this regard, data derived from clinical and experimental studies have demonstrated that the receptor of advanced glycation end-products (RAGE)/AGEs axis plays an important role in the onset of a crucial and long-lasting inflammatory milieu, thus supporting tumor growth and development. AGEs are formed in biological systems or foods, and food-derived AGEs, also known as dietary AGEs are known to contribute to the systemic pool of AGEs. Once they bind to RAGE, the activation of multiple and crucial signaling pathways are triggered, thus favoring the secretion of several proinflammatory cytokines also involved in the promotion of gallbladder cancer invasion and migration. In the present review, we aimed to highlight the relevance of the association between high dietary AGEs intakes and high risk for gallbladder cancer, and emerging data supporting that dietary intervention to reduce gallbladder cancer risk is a very attractive approach that deserves much more research efforts.

Keywords: Gallbladder cancer, Advanced glycation end-products, Receptor of advanced glycation end-products, Chronic inflammation, Nutrition

Core tip: A growing body of data has demonstrated a positive association between the risk of gallbladder cancer and high dietary intake of advanced glycation end-products (AGEs). These noxious compounds are important contributors to the onset of a chronic inflammatory response, through the activation of the receptor of AGEs (RAGE). We herein discuss how RAGE activation is crucial in the development of gallbladder cancer and the relevance of new incoming data supporting the role of dietary interventions to reduce the risk of gallbladder cancer.